Insud Pharma
Laura C. currently serves as the Head of Finance at Kevilmare Corporativo BV, having started in January 2024. In addition, Laura holds the position of Senior Global Intercompany Controller at Insud Pharma since May 2022, overseeing intercompany financial planning and reporting. Previous roles include Senior Finance & Business Controller at Affidea España, Corporate Finance FP&A at Axa Mediterranean Holding, and various finance-related positions at GSK. Laura's career began at American Airlines as a Banking & Taxation Accountant. Educational credentials include a Bachelor of Business Administration from Universidad Complutense de Madrid, a CIMA qualification, and specialized courses from Harvard University and Aglaia Consulting.
This person is not in any offices
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.